16. Earnings; Asset and Financial Position of the Bayer Group

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "16. Earnings; Asset and Financial Position of the Bayer Group"

Transcription

1 Bayer Annual Report Earnings; Asset and Financial Position of the Bayer Group 16.1 Earnings Performance of the Bayer Group Bayer Group Summary Income Statements [Table ] Change million million % Net sales 40,157 42, Cost of goods sold 19,516 20, Selling expenses 10,312 11, Research and development expenses 3,406 3, General administration expenses 1,712 1, Other operating income (+) and expenses ( ) (277) (134) EBIT 1 4,934 5, Financial result (727) (981) 34.9 Income before income taxes 4,207 4, Income taxes (1,021) (1,082) 6.0 Income after income taxes 3,186 3, of which attributable to non-controlling interest (3) 17 of which attributable to Bayer AG stockholders (net income) 3,189 3, figures restated 1 EBIT = earnings before financial result and taxes of the Bayer Group rose to 42,239 million (+ 5.2%). The increase after adjusting for currency and portfolio effects was 7.2%. The cost of goods sold increased by 3.8% to 20,266 million, mainly due to higher volumes at HealthCare and MaterialScience. The ratio of the cost of goods sold to total sales was 48.0% (: 48.6%). The selling expenses of 11,018 million (+ 6.8%) amounted to 26.1% of sales (: 25.7%). Research and development (r&d) expenses rose in by 4.9% to 3,574 million, the increase being attributable to HealthCare and CropScience. The ratio of r&d expenses to sales remained level at 8.5% (: 8.5%). General administration expenses, at 1,741 million, were slightly above the prior year (+ 1.7%). The ratio of general administration expenses to total sales was somewhat lower at 4.1% (: 4.3%). The negative balance of other operating income and expenses was reduced considerably to minus 134 million (: minus 277 million), mainly because special charges for accounting measures related to legal claims were lower in (see also Chapter 16.2 Calculation of E Before Special Items ). ebit climbed by 11.6% in to 5,506 million.

2 170 Bayer Annual Report The financial result fell by 34.9% to minus 981 million. It comprised 356 million (: 355 million) in net interest expense, 322 million (: 297 million) in interest cost for pension and other provisions, and a 248 million (: 120 million) net exchange loss. The year-on-year increase in the net exchange loss was mainly due to exchange rate effects in Venezuela, Ukraine and Argentina, higher exchange hedging costs and the fact that the prior year s financial result included a one-time gain of 77 million from the sale of Bayer s interest in Onyx Pharmaceuticals Inc., United States. Tax expense in increased to 1,082 million as a result of earnings growth (: 1,021 million). Income after income taxes came in at 3,443 million. Income attributable to non-controlling interest rose by 20 million to 17 million. Bayer Group net income for was 3,426 million (: 3,189 million) Calculation of EBIT(DA) Before Special Items Key performance indicators for the Bayer Group are ebit before special items and ebitda before special items. These indicators are reported in order to allow a more accurate assessment of business operations. The special items comprising effects that are non-recurring or do not regularly recur or attain similar magnitudes are detailed in the following table. ebitda, ebitda before special items and ebit before special items are not defined in the International Financial Reporting Standards (ifrs) and should therefore be regarded only as supplementary information. ebitda before special items is a meaningful indicator of operating performance since it is not affected by depreciation, amortization, impairment losses, impairment loss reversals or special items. By reporting this indicator, the company aims to give readers a clear picture of the results of operations and ensure comparability of data over time. The ebitda margin before special items, which is the ratio of ebitda before special items to sales, serves as a relative indicator for the internal and external comparison of operational earning power. Depreciation, amortization and impairment losses increased by 1.4% in to 2,936 million (: 2,896 million), comprising 1,592 million (: 1,572 million) in amortization and impairments of intangible assets, 2 million (: 13 million) in impairment loss reversals and 1,346 million (: 1,337 million) in depreciation and impairments of property, plant and equipment. A total of 68 million (: 268 million) in depreciation, amortization and impairments constituted special items. This amount comprised 70 million (: 259 million) in impairment losses and 0 million (: 22 million) in depreciation and amortization, less 2 million (: 13 million) in impairment loss reversals.

3 Bayer Annual Report 171 Special Items Reconciliation [Table ] EBIT 1 EBIT 1 EBIT 1 EBIT 1 EBITDA² EBITDA² EBITDA² EBITDA² million million million million million million million million Before special items 1,094 1,003 5,773 5,944 1,769 1,846 8,401 8,812 HealthCare (354) (376) (713) (331) (268) (347) (476) (298) Impairment losses / impairment loss reversals (55) (29) (171) (29) 14 Restructuring (109) (197) (78) (145) Litigations (180) (88) (269) (88) (180) (88) (269) (88) Integration costs (10) (86) (76) (153) (10) (86) (76) (149) Settlement of pre-existing relationship Divestitures (173) (96) (173) (96) CropScience (40) (32) (72) (32) (37) (2) (64) (2) Restructuring (40) (67) (37) (59) Litigations (1) (5) (1) (1) (5) (1) Divestitures (31) (31) (1) (1) MaterialScience (18) (22) 6 (43) (4) (21) 29 (38) Restructuring (18) (22) (36) (43) (4) (21) (13) (38) Divestitures Reconciliation (27) (12) (60) (32) (27) (12) (60) (32) Restructuring (25) (12) (58) (32) (25) (12) (58) (32) Litigations (2) (2) (2) (2) Total special items (439) (442) (839) (438) (336) (382) (571) (370) of which cost of goods sold (79) (68) (116) (80) (42) (37) (83) (49) of which selling expenses (37) (50) (73) (63) (37) (21) (73) (34) of which research and development expenses (77) 1 (212) (2) (12) 1 1 (2) of which general administration expenses (38) (23) (56) (55) (35) (23) (53) (51) of which other operating income / expenses (208) (302) (382) (238) (210) (302) (363) (234) After special items ,934 5,506 1,433 1,464 7,830 8,442 1 EBIT = earnings before financial result and taxes 2 EBITDA = EBIT plus amortization and impairment losses on intangible assets, plus depreciation and impairment losses on property, plant and equipment, minus impairment loss reversals 3 For details see Note [6.2] to the consolidated financial statements 16.3 Core Earnings Per Share Earnings per share according to ifrs are affected by the purchase price allocation for acquisitions and other special factors. To enhance comparability, we also determine core net income after eliminating amortization and impairment losses / impairment loss reversals of intangible assets, impairment losses / impairment loss reversals of property, plant and equipment and special items, and the related tax effects. From this core net income we calculate core earnings per share in the same way as earnings per share. Core earnings per share form the basis for our dividend policy. Core earnings per share in rose by 7.3% to 6.02 (: 5.61).

4 172 Bayer Annual Report Core Earnings per Share [Table ] million million million million EBIT (as per income statements) ,934 5,506 Amortization and impairment losses / loss reversals on intangible assets ,559 1,590 Impairment losses / loss reversals on property, plant and equipment Special items (other than amortization and impairment losses / loss reversals) Core EBIT 1,449 1,507 7,112 7,562 Financial result (as per income statements) (84) (347) (727) (981) Special items in the financial result (72) Income taxes (as per income statements) (129) 16 (1,021) (1,082) Special items in income taxes Tax effects related to amortization, impairment losses / loss reversals and special items (266) (246) (734) (576) Income after income taxes attributable to non-controlling interest (as per income statements) 13 (6) 3 (17) Core net income ,643 4,977 Shares Shares Shares Shares Number of issued ordinary shares 826,947, ,947, ,947, ,947,808 Core earnings per share ( ) Consolidatd Financial Statements Note 16 The calculation of earnings per share in accordance with ifrs is explained in Note [16] to the consolidated financial statements. Core net income, core earnings per share and core ebit are not defined in ifrs Value Management SYSTEM BASED ON CASH VALUE ADDED The principal value-based steering parameters in the Bayer Group are the cash value added (cva) and the cash flow return on investment (cfroi). If the cva is positive, the respective company or business entity has exceeded the minimum requirements of the equity and debt capital providers and has created value. The cfroi is a ratio indicating the profitability of the Group or of individual business entities and must be compared to the cost of capital. CALCULATING THE COST OF CAPITAL Bayer calculates the cost of capital according to the debt / equity ratio at the beginning of the year using the weighted average cost of capital (wacc) formula. The cost of equity capital is the return expected by stockholders, computed from capital market information. The cost of debt capital used in calculating wacc is based on the terms for ten-year Eurobonds issued by industrial companies with an a rating. Cost of capital for the Bayer Group 7.6% To take into account the different risk and return profiles of our principal businesses, we calculate individual capital cost factors after income taxes for each of our subgroups. These were 7.9% for HealthCare, 7.3% for CropScience and 6.9% for MaterialScience. The capital cost factor for the Group as a whole in was 7.6%.

5 Bayer Annual Report 173 GROSS CASH FLOW, CASH VALUE ADDED AND CASH FLOW RETURN ON INVESTMENT AS PERFORMANCE YARDSTICKS The gross cash flow is the measure of our internal financing capability. Bayer has chosen this parameter because it is relatively free of accounting influences and is therefore a more meaningful performance indicator. Taking into account the costs of capital and of reproducing depletable assets, we determine the gross cash flow hurdle. If the gross cash flow hurdle is exceeded, the cva is positive and thus the required return on equity and debt plus the cost of asset reproduction has been earned. Positive CVA = value created The cfroi is the difference between the gross cash flow and the cost of reproducing depletable assets, divided by the capital invested. The capital invested is calculated from the statement of financial position and basically comprises the property, plant and equipment and intangible assets required for operations stated at the historical cost of acquisition or construction plus working capital, less interestfree liabilities (such as current provisions). To mitigate the effect of fluctuations in the capital invested during the year, the cfroi is computed on the basis of the average capital invested for the respective year. The gross cash flow hurdle for was 4,447 million. Actual gross cash flow came in at 6,820 million, exceeding the hurdle by 53.4%. Thus the entire cost of capital and asset reproduction costs were earned in. The positive cva of 2,373 million shows that Bayer exceeded the minimum return and reproduction requirements and created value. A cfroi of 11.9% was achieved in. HealthCare and CropScience exceeded their required returns (including asset reproduction), raised their cva and helped to increase the value of the Group. In MaterialScience reduced the gap to the gross cash flow hurdle, which continues to be impacted by growth investments. Value Management Indicators by Subgroup [Table ] HealthCare CropScience MaterialScience Bayer Group million million million million million million million million Gross cash flow 1 (GCF) 3,573 4,011 1,590 1, ,832 6,820 Gross cash flow hurdle 2,109 2, ,060 1,025 4,260 4,447 Cash value added (CVA) 1,464 1, (173) (64) 1,572 2,373 Cash flow return on investment (CFROI) 14.1% 13.4% 14.2% 15.3% 5.5% 6.0% 11.1% 11.9% WACC 7.9% 7.9% 7.3% 7.3% 6.9% 6.9% 7.6% 7.6% Average capital invested 22,480 26,784 9,881 10,841 10,371 10,524 43,548 48,934 Delta cash value added is not listed due to its limited importance. 1 For definition see Chapter 16.5 Liquidity and Capital Expenditures of the Bayer Group.

6 174 Bayer Annual Report 16.5 Liquidity and Capital Expenditures of the Bayer Group Bayer Group Summary Statements of Cash Flows [Table ] million million Gross cash flow 1 5,832 6,820 Changes in working capital / other non-cash items (661) (1,010) Net cash provided by (used in) operating activities (net cash flow) 5,171 5,810 Net cash provided by (used in) investing activities (2,581) (15,539) Net cash provided by (used in) financing activities (2,535) 9,736 Change in cash and cash equivalents due to business activities 55 7 Cash and cash equivalents at beginning of period 1,698 1,662 Change due to exchange rate movements and to changes in scope of consolidation (91) 184 Cash and cash equivalents at end of period 1,662 1,853 1 Gross cash flow = income after income taxes, plus income taxes, plus financial result, minus income taxes paid or accrued, plus depreciation, amortization and impairment losses, minus impairment loss reversals, plus / minus changes in pension provisions, minus gains / plus losses on retirements of noncurrent assets, minus gains from the remeasurement of already held assets in step acquisitions. The change in pension provisions includes the elimination of non-cash components of EBIT. It also contains benefit payments during the year. OPERATING CASH FLOW Gross cash flow climbed by 16.9% in to 6,820 million (: 5,832 million), mainly because of the improvement in ebit. Net cash flow moved ahead by 12.4% to 5,810 million (: 5,171 million), after a business-related increase in cash tied up in working capital and 778 million in deferred income from the one-time payment received in connection with the sgc collaboration with Merck & Co., Inc., United States. Income taxes paid in amounted to 1,835 million (: 1,281 million). INVESTING CASH FLOW Net cash outflow for investing activities in amounted to 15,539 million. Cash outflows for property, plant and equipment and intangible assets were 10% higher at 2,371 million (: 2,157 million) and included 832 million (: 809 million) at HealthCare, 686 million (: 538 million) at CropScience and 605 million (: 559 million) at MaterialScience. The 13,545 million (: 1,082 million) in outflows for acquisitions mainly related to the purchases of the consumer care businesses of Merck & Co., Inc., United States, and Algeta asa, Norway. Cash outflows from noncurrent and current financial assets amounted to 177 million (: inflow of 301 million). Inflows from interest and dividends totaled 107 million (: 125 million).

7 Bayer Annual Report 175 The principal strategic capital expenditures for property, plant and equipment in the operating segments within the past two years are listed in the following table: Capital Expenditures for Property, Plant and Equipment [Table ] Segment CAPITAL EXPENDITURES Pharmaceuticals Description Expansion of Xarelto TM production capacities in Wuppertal and Leverkusen, Germany Expansion of production capacities for new rfactor VIII therapies in Wuppertal, Germany Expansion of R&D laboratory capacities in Wuppertal, Germany Modernization of research facilities in Berlin, Germany Expansion of production capacities in Beijing, China Expansion of Quality Control Biologics in Berkeley, California, United States Consumer Health CropScience Completion of capacity expansion for fungicides in Germany and Switzerland Completion of capacity expansion for herbicides in Germany Establishment of breeding stations for various plant species worldwide MaterialScience Doubling of production capacities for polycarbonates in Shanghai, China Doubling of production capacities for hexamethylene diisocyanate (HDI) in Shanghai, China Completion of capacity expansion for diphenylmethane diisocyanate (MDI) in Shanghai, China Construction of a world-scale production complex for toluene diisocyanate (TDI) based on gas-phase phosgenation technology in Dormagen, Germany CAPITAL EXPENDITURES Pharmaceuticals Consolidation of multiple administrative and business operations in Whippany, New Jersey, United States Expansion of Xarelto TM production capacities in Wuppertal and Leverkusen, Germany Expansion of production capacities for biologics in Wuppertal, Germany Consumer Health CropScience Capacity expansion and process modifications for the production of fungicides in Germany, Switzerland, and the United States and for related formulating units in France Expansion of manufacturing capacities for herbicidal active ingredients in Germany and the United States Establishment of breeding stations for wheat in Europe, North America, and Asia / Pacific; for soybeans in North America and Latin America; and for other crops and trait development MaterialScience Doubling of production capacities for polycarbonates in Shanghai, China Expansion of production capacities for diphenylmethane diisocyanate (MDI) in Shanghai, China Construction of a world-scale production complex for toluene diisocyanate (TDI) based on gas-phase phosgenation technology in Dormagen, Germany Completion of a multi-purpose facility for aliphatic isocyanates - hexamethylene diisocyanate (HDI) and isophorone diisocyanate (IPDI) - in Leverkusen, Germany

8 176 Bayer Annual Report FINANCING CASH FLOW Net cash inflow for financing activities in amounted to 9,736 million, including net borrowings of 11,838 million (: net loan repayments of 619 million). Net interest payments were 7% higher at 362 million (: 338 million). The cash outflow for dividends amounted to 1,739 million (: 1,574 million). LIQUID ASSETS AND NET FINANCIAL DEBT Net Financial Debt [Table ] Dec. 31, Dec. 31, million million Bonds and notes / promissory notes 4,520 14,964 of which hybrid bonds 1 1,344 4,552 Liabilities to banks 2,302 3,835 Liabilities under finance leases Liabilities from derivatives Other financial liabilities 1,516 1,976 Positive fair values of hedges of recorded transactions (504) (258) Financial liabilities 8,526 21,600 Cash and cash equivalents (1,662) (1,853) Current financial assets (133) (135) Net financial debt 6,731 19,612 1 classified as debt according to IFRS Net financial debt of the Bayer Group increased in to 19.6 billion, mainly as a result of cash outflows for acquisitions. As of December 31,, the Group had cash and cash equivalents of 1.9 billion (: 1.7 billion). Financial liabilities at the end of the reporting period amounted to 21.6 billion (: 8.5 billion), with three subordinated hybrid bonds reflected at 4.6 billion overall. Net financial debt should be viewed against the fact that Moody s and Standard & Poor s treat 75% and 50%, respectively, of the hybrid bond issued in July 2005 with a nominal volume of 1.3 billion as equity. Moody s and Standard & Poor s treat 50% of the hybrid bonds issued in July with nominal volumes of 1.75 billion and 1.5 billion, respectively, as equity. The hybrid bonds thus have a more limited effect on the Group s rating-specific debt indicators than conventional borrowings. Our noncurrent financial liabilities increased in from 5.6 billion to 18.5 billion, while current financial liabilities remained unchanged at 3.4 billion.

9 Bayer Annual Report Asset and Capital Structure of the Bayer Group Bayer Group Summary Statements of Financial Position [Table ] Dec. 31, Dec. 31, Change million million % Noncurrent assets 32,289 48, Current assets 19,028 22, Total assets 51,317 70, Equity 20,804 20, Noncurrent liabilities 16,490 34,513. Current liabilities 14,023 15, Liabilities 30,513 50, Total equity and liabilities 51,317 70, Total assets as of December 31,, increased by 36.9% to 70.2 billion. Noncurrent assets rose by 48.7% to 48.0 billion due mainly to acquisitions. This was due to the 6.3 billion increase in goodwill and the 6.7 billion rise in other intangible assets. The carrying amount of current assets climbed to 22.2 billion. Equity was lower by 0.6 billion at 20.2 billion. The positive effects from the net income of 3.4 billion and the exchange differences of 1.4 billion (: negative effect of 0.7 billion) were offset by the negative effect from the increase of 3.5 billion (: positive effect from the decline of 1.3 billion) recognized outside profit or loss in post-employment benefit obligations and the dividend payment of 1.7 billion (: 1.6 billion). The equity ratio (equity coverage of total assets) as of December 31, was 28.8% (: 40.5%). Liabilities increased by 19.5 billion compared with December 31,, to 50.0 billion, due to the acquisition-related 12.8 billion increase in financial liabilities and the 4.9 billion increase in provisions for pensions and other post-employment benefits. Net Defined Benefit Liability for Post-Employment Benefits [Table ] Dec. 31, Dec. 31, million million Provisions for pensions and other post-employment benefits 7,368 12,236 Net defined benefit asset (117) (41) Net defined benefit liability for post-employment benefits 7,251 12,195 The net defined benefit liability for pensions and other post-employment benefits increased from 7.3 billion to 12.2 billion in, mainly due to a decline in long-term capital market interest rates for high-quality corporate bonds.

10 178 Bayer Annual Report Ratios [Table ] Cost of sales ratio (%) R & D expense ratio (%) Return on sales in (%) EBIT margin (%) EBITDA margin before special items (%) Asset intensity (%) Reinvestment ratio (%) Liability structure (%) Gearing Free operating cash flow ( million) Inventory turnover Receivables turnover Payables turnover Equity ratio (%) Return on equity (%) Return on assets (%) figures restated 1 property, plant and equipment Cost of goods sold Research and development expenses Income after income taxes EBIT EBITDA before special items Property, plant and equipment + intangible assets Total assets Capital expenditures Depreciation 1 Current liabilities Liabilities Net debt + pension provisions Equity Net operating cash flow less cash outflows for property, plant and equipment 3,014 3,439 and intangible assets Cost of goods sold Inventories Trade accounts receivable Cost of goods sold Trade accounts payable Equity Total assets Income after income taxes Average equity Income before income taxes and interest expense Average total assets

11 Bayer Annual Report Financial Management of the Group The financial management of the Bayer Group is conducted by the strategic management holding company Bayer AG. Capital is a global resource, generally procured centrally and distributed within the Group. The foremost objectives of our financial management are to help bring about a sustained increase in corporate value and to ensure the Group s liquidity and creditworthiness. This involves optimizing the capital structure and effectively managing risks. The management of currency, interest rate, raw material price and default risks helps to reduce the volatility of our earnings. The contracted rating agencies assess Bayer as follows: Rating [Table ] Long-term rating Outlook Short-term rating Standard & Poor s A stable A 2 Moody s A3 stable P 2 These credit ratings reflect the company s high solvency and ensure access to a broad investor base for financing purposes. It remains our goal to achieve and maintain financial ratios that support an a category rating in order to maintain our financial flexibility. We pursue a prudent debt management strategy to ensure flexibility, drawing on a balanced financing portfolio. This is based on bonds predominantly a multi-currency European Medium Term Notes program, syndicated credit facilities, bilateral loan agreements and a global commercial paper program. We use financial derivatives to hedge against risks arising from business operations or financial transactions, but do not employ contracts in the absence of an underlying transaction. It is our policy to diminish default risks by selecting trading partners with a high credit standing. We closely monitor the execution of all transactions, which are conducted in accordance with Group directives. Further details of our risk management objectives and the ways in which we account for all the major types of hedged transactions along with price, credit and liquidity risks as they relate to the use of financial instruments are given in Chapter 20.3 Opportunities and Risks Report.

Consolidated Statement of Profit or Loss (in million Euro)

Consolidated Statement of Profit or Loss (in million Euro) Consolidated Statement of Profit or Loss (in million Euro) Q2 2012 Q2 2013 % H1 2012 H1 2013 % Restated * change Restated * change Revenue 779 732-6.0% 1,513 1,437-5.0% Cost of sales (553) (521) -5.8%

More information

Strong start to the year for Bayer

Strong start to the year for Bayer 4 Bayer Interim Report Interim Group Management Report as of March 31, First quarter of Strong start to the year for Bayer // Significant sales and earnings growth at HealthCare // CropScience performance

More information

Consolidated Statement of Profit or Loss (in million Euro)

Consolidated Statement of Profit or Loss (in million Euro) Consolidated Statement of Profit or Loss (in million Euro) Q3 2014 Q3 2015 % change 9m 2014 9m 2015 % change Revenue 636 661 3.9% 1,909 1,974 3.4% Cost of sales (440) (453) 3.0% (1,324) (1,340) 1.2% Gross

More information

Consolidated Statement of Profit or Loss (in million Euro)

Consolidated Statement of Profit or Loss (in million Euro) Consolidated Statement of Profit or Loss (in million Euro) FY 2014 FY 2015 % change Q4 2014 Q4 2015 % change un Revenue 2,620 2,646 1.0% 711 672-5.5% Cost of sales (1,813) (1,804) -0.5% (489) (464) -5.1%

More information

Consolidated Statement of Profit or Loss (in million Euro)

Consolidated Statement of Profit or Loss (in million Euro) Consolidated Statement of Profit or Loss (in million Euro) FY 2013 FY 2014 % change Q4 2013 Q4 2014 % change un Revenue 2,865 2,620-8.6% 739 711-3.8% Cost of sales (2,031) (1,813) -10.7% (511) (489) -4.3%

More information

Consolidated Statement of Profit or Loss (in million Euro)

Consolidated Statement of Profit or Loss (in million Euro) Consolidated Statement of Profit or Loss (in million Euro) Q3 2013 Q3 2014 % change 9m 2013 9m 2014 % change Revenue 689 636-7.7% 2,126 1,909-10.2% Cost of sales (497) (440) -11.5% (1,520) (1,324) -12.9%

More information

Financial Results. siemens.com

Financial Results. siemens.com s Financial Results Fourth Quarter and Fiscal 2015 siemens.com Key figures (in millions of, except where otherwise stated) Volume Q4 % Change Fiscal Year % Change FY 2015 FY 2014 Actual Comp. 1 2015 2014

More information

Interim management statement

Interim management statement Interim management statement 1st quarter of 2016 FIRST QUARTER AT A GLANCE DEUTZ Group: Overview DEUTZ Group: Segments New orders 327.3 321.0 Unit sales (units) 32,112 36,907 Revenue 300.2 318.1 EBITDA

More information

Consolidated balance sheet

Consolidated balance sheet 83 Consolidated balance sheet December 31 Non-current assets Goodwill 14 675.1 978.4 Other intangible assets 14 317.4 303.8 Property, plant, and equipment 15 530.7 492.0 Investment in associates 16 2.5

More information

2015 Quarterly Report II

2015 Quarterly Report II 2015 Quarterly Report II 2 Key data Eckert & Ziegler 01 06/2015 01 06/2014 Change Sales million 69.0 61.9 + 11 % Return on revenue before tax % 16 % 9 % + 87 % EBITDA million 15.6 9.7 + 61 % EBIT million

More information

Press release Regulated information

Press release Regulated information Press release Regulated information 26 February 2010 Annual results 2009 Press Katelijn Bohez T +32 56 23 05 71 Investor Relations Jacques Anckaert T +32 56 23 05 72 www.bekaert.com www.bekaert.mobi Bekaert

More information

HORNBACH Baumarkt AG Group Q3/9M 2016/2017

HORNBACH Baumarkt AG Group Q3/9M 2016/2017 HORNBACH Baumarkt AG Group Q3/9M 2016/2017 Quarterly Statement as of November 30, 2016 2 HORNBACH BAUMARKT AG GROUP QUARTERLY STATEMENT: 3 RD QUARTER OF 2016/2017 HORNBACH BAUMARKT AG GROUP Statement on

More information

ITRON, INC. CONSOLIDATED STATEMENTS OF OPERATIONS

ITRON, INC. CONSOLIDATED STATEMENTS OF OPERATIONS , INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, in thousands, except per share data) Revenues $ 497,590 $ 446,746 Cost of revenues 334,387 308,324 Gross profit 163,203 138,422 Operating expenses

More information

Earnings Release Q3 FY 2015 April 1 to June 30, 2015

Earnings Release Q3 FY 2015 April 1 to June 30, 2015 Munich, Germany, July 30, 2015 Earnings Release FY 2015 April 1 to June 30, 2015 Solid performance, softening market environment»overall our businesses delivered solid underlying profitability despite

More information

5N PLUS INC. Condensed Interim Consolidated Financial Statements (Unaudited) For the three month periods ended March 31, 2016 and 2015 (in thousands

5N PLUS INC. Condensed Interim Consolidated Financial Statements (Unaudited) For the three month periods ended March 31, 2016 and 2015 (in thousands Condensed Interim Consolidated Financial Statements (Unaudited) (in thousands of United States dollars) Condensed Interim Consolidated Statements of Financial Position (in thousands of United States dollars)

More information

Stockholders Newsletter

Stockholders Newsletter k COVER PICTURE Stockholders Newsletter FINANCIAL REPORT AS OF SEPTEMBER 30, Third quarter of Bayer operationally strong / strategic focus on Life Science businesses CONTENTS INTERIM GROUP MANAGEMENT REPORT

More information

HORNBACH Holding AG & Co. KGaA Group Q3/9M 2016/2017

HORNBACH Holding AG & Co. KGaA Group Q3/9M 2016/2017 HORNBACH Holding AG & Co. KGaA Group Q3/9M 2016/2017 Quarterly Statement as of November 30, 2016 2 HORNBACH HOLDING AG & CO. KGaA GROUP QUARTERLY STATEMENT: 3 RD QUARTER OF 2016/2017 HORNBACH HOLDING AG

More information

Full Year Results 2012. Conference Call Presentation, 21 st March 2013

Full Year Results 2012. Conference Call Presentation, 21 st March 2013 Full Year Results 2012 Conference Call Presentation, 21 st March 2013 0 Disclaimer This presentation may contain forward-looking statements based on current assumptionsandforecastsmadebybrenntag AG and

More information

EBITDA, EBITDA margin, EBIT and EBIT margin

EBITDA, EBITDA margin, EBIT and EBIT margin Interim Group Report 0106/2016 Key financial performance indicators for the Lenzing Group will be described here in detail. For the most part, they are derived from the Lenzing Group s condensed consolidated

More information

Schaeffler Group at a glance

Schaeffler Group at a glance Facts and figures First quarter 2016 Schaeffler Group at a glance Key figures Income statement (in millions) 2016 2015 Change Revenue 3,343 3,339 0.1 % at constant currency 2.4 % EBIT 421 434-3.0 % in

More information

Earnings Release Q2 FY 2015 January 1 to March 31, 2015

Earnings Release Q2 FY 2015 January 1 to March 31, 2015 Munich, Germany, May 7, 2015 Earnings Release FY 2015 January 1 to March 31, 2015 Portfolio gains drive income»for business volume, we performed well in our markets. The profitability of our Industrial

More information

3. CONSOLIDATED QUARTERLY FINANCIAL STATEMENTS

3. CONSOLIDATED QUARTERLY FINANCIAL STATEMENTS 3. CONSOLIDATED QUARTERLY FINANCIAL STATEMENTS (1) Consolidated Quarterly Balance Sheets September 30, 2014 and March 31, 2014 Supplementary Information 2Q FY March 2015 March 31, 2014 September 30, 2014

More information

Consolidated and Non-Consolidated Financial Statements

Consolidated and Non-Consolidated Financial Statements May 13, 2016 Consolidated and Non-Consolidated Financial Statements (For the Period from April 1, 2015 to March 31, 2016) 1. Summary of Operating Results (Consolidated) (April 1,

More information

GrandVision reports Revenue growth of 13.8% and EPS growth of 31.7%

GrandVision reports Revenue growth of 13.8% and EPS growth of 31.7% GrandVision reports Revenue of 13.8% and EPS of 31.7% Schiphol, the Netherlands 16 March 2015. GrandVision NV (EURONEXT: GVNV) publishes Full Year and Fourth Quarter 2015 results. 2015 Highlights Revenue

More information

Group Quarterly Statement January March 2016

Group Quarterly Statement January March 2016 Sharing values Growing Together Group Quarterly Statement January March 2016 Group sales increase 10 % to 732 million Sales increase 14 % compared to the previous year at local currency Solid growth in

More information

Half year results 2011

Half year results 2011 Half year results 2011 29 July 2011 Bert De Graeve, Chief Executive Officer Bruno Humblet, Chief Financial Officer Address by Bert De Graeve, Chief Executive Officer Introductory remark The consolidated

More information

Strong first quarter sales growth in all business groups

Strong first quarter sales growth in all business groups Strong first quarter sales growth in all business groups Agfa-Gevaert announced its first quarter results. All business groups reported solid sales, leading to an increase in Group sales of 8.1 percent

More information

Preliminary Consolidated Financial Statements 2015 >

Preliminary Consolidated Financial Statements 2015 > Preliminary Consolidated Financial Statements 2015 > The following results and amounts are preliminary statements that have not yet been approved or adopted by the Supervisory Board. Preliminary Consolidated

More information

Reporting and Analyzing Cash Flows. Learning Objectives coverage by question 34, 35, 36, 37, 38, 39, 40, 41, 42, 43

Reporting and Analyzing Cash Flows. Learning Objectives coverage by question 34, 35, 36, 37, 38, 39, 40, 41, 42, 43 Chapter 4 Reporting and Analyzing Cash Flows Learning Objectives coverage by question Mini-exercises Exercises Problems Cases LO1 Explain the purpose of the statement of cash flows and how it complements

More information

Residual carrying amounts and expected useful lives are reviewed at each reporting date and adjusted if necessary.

Residual carrying amounts and expected useful lives are reviewed at each reporting date and adjusted if necessary. 87 Accounting Policies Intangible assets a) Goodwill Goodwill represents the excess of the cost of an acquisition over the fair value of identifiable net assets and liabilities of the acquired company

More information

GrandVision reports 2.8 billion Revenue and 449 million EBITDA for 2014

GrandVision reports 2.8 billion Revenue and 449 million EBITDA for 2014 GrandVision reports 2.8 billion Revenue and 449 million EBITDA for 2014 Schiphol, the Netherlands 18 March 2015. GrandVision N.V. publishes Full Year and Quarter 2014 results. 2014 Highlights Revenue grew

More information

Logwin AG. Nine-Month Financial Report 2014

Logwin AG. Nine-Month Financial Report 2014 Logwin AG Nine-Month Financial Report 2014 Key Figures 1 January 30 September 2014 Earnings position In thousand EUR 2014 2013 Revenues Group 842,390 932,384 Change on 2013-9.7 % Solutions 366,604 470,658

More information

Office Depot Announces First Quarter 2012 Results. May 1, :02 AM ET

Office Depot Announces First Quarter 2012 Results. May 1, :02 AM ET Office Depot Announces First Quarter 2012 Results May 1, 2012 7:02 AM ET BOCA RATON, Fla., May 01, 2012 (BUSINESS WIRE) --Office Depot, Inc. (NYSE: ODP), a leading global provider of office supplies and

More information

CONSOLIDATED STATEMENT OF INCOME

CONSOLIDATED STATEMENT OF INCOME CONSOLIDATED STATEMENT OF INCOME 4 th quarter (a) 3 rd quarter 4 th quarter 2009 Sales 40,157 40,180 36,228 Excise taxes (4,397) (4,952) (4,933) Revenues from sales 35,760 35,228 31,295 Purchases, net

More information

Consolidated Statements of Profit or Loss Ricoh Company, Ltd. and Consolidated Subsidiaries For the Years Ended March 31, 2014 and 2015

Consolidated Statements of Profit or Loss Ricoh Company, Ltd. and Consolidated Subsidiaries For the Years Ended March 31, 2014 and 2015 Consolidated Statements of Profit or Loss Sales: Products 1,041,794 1,071,446 8,928,717 Post sales and rentals 1,064,555 1,068,678 8,905,650 Other revenue 89,347 91,818 765,150 Total sales 2,195,696 2,231,942

More information

Earnings Release Q1 FY 2016 October 1 to December 31, 2015

Earnings Release Q1 FY 2016 October 1 to December 31, 2015 Munich, Germany, January 25, 2016 Earnings Release FY 2016 October 1 to December 31, 2015 Strong start into the fiscal year earnings outlook raised»we delivered a strong quarter and are well underway in

More information

Quarterly Financial Report of Fresenius Group

Quarterly Financial Report of Fresenius Group Quarterly Financial Report of Fresenius Group applying United States Generally Accepted Accounting Principles (U.S. GAAP) 1 st 3 rd Quarter and 3 rd Quarter 2015 2 TABLE OF CONTENTS 3 Fresenius Group figures

More information

Significant investment in Slovenia and bond issuance

Significant investment in Slovenia and bond issuance DDM DEBT AB (publ) Corporate Registration Number: 559053-6230 Interim Report Q3 1 July 30 September Significant investment in Slovenia and bond issuance Highlights third quarter Net collections of EUR

More information

Office Depot Announces Third Quarter 2012 Results. November 6, :01 AM ET

Office Depot Announces Third Quarter 2012 Results. November 6, :01 AM ET Office Depot Announces Third Quarter 2012 Results November 6, 2012 7:01 AM ET BOCA RATON, Fla.--(BUSINESS WIRE)--Nov. 6, 2012-- Office Depot, Inc. (NYSE: ODP), a leading global provider of office supplies

More information

N O R M A G R O U P S E

N O R M A G R O U P S E NORMA GROUP SE Overview of Key Figures 2016 Q1 2016 Q1 2015 change in % Order situation Order book (31 Mar) EUR millions 284.7 300.0 5.1 Income statement Revenue EUR millions 226.6 221.5 2.3 Gross profit

More information

Management s Review. For more details, please see the Management s Review in the Consolidated Financial Statements.

Management s Review. For more details, please see the Management s Review in the Consolidated Financial Statements. Management s Review Principal activities Arla Foods amba and its subsidiary enterprises operate dairy activities based on milk weighed in by its members in Denmark, Sweden, Germany and now also the United

More information

Note 2 SIGNIFICANT ACCOUNTING

Note 2 SIGNIFICANT ACCOUNTING Note 2 SIGNIFICANT ACCOUNTING POLICIES BASIS FOR THE PREPARATION OF THE FINANCIAL STATEMENTS The consolidated financial statements have been prepared in accordance with International Financial Reporting

More information

Consolidated Statement of Profit or Loss

Consolidated Statement of Profit or Loss Consolidated Statement of Profit or Loss Sales: Products 864,699 1,041,794 $ 10,114,505 Post sales and rentals 941,610 1,064,555 10,335,485 Other revenue 79,686 89,347 867,447 Total sales 1,885,995 2,195,696

More information

Consolidated Balance Sheets

Consolidated Balance Sheets Consolidated Balance Sheets March 31 2015 2014 2015 Assets: Current assets Cash and cash equivalents 726,888 604,571 $ 6,057,400 Marketable securities 19,033 16,635 158,608 Notes and accounts receivable:

More information

March 31, 2014 Income from operations... $ 121,521 $ 136,082 $ 120,847

March 31, 2014 Income from operations... $ 121,521 $ 136,082 $ 120,847 Akamai Technologies, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures In addition to providing financial measurements based on generally accepted accounting principles in the United States of

More information

International Accounting Standard 7 Statement of cash flows *

International Accounting Standard 7 Statement of cash flows * International Accounting Standard 7 Statement of cash flows * Objective Information about the cash flows of an entity is useful in providing users of financial statements with a basis to assess the ability

More information

2014 Quarterly Report II

2014 Quarterly Report II 2014 Quarterly Report II 2 Key data Eckert & Ziegler 01 06/2014 01 06/2013 Change Sales million 61.9 55.3 12% Return on revenue before tax % 9 % 12 % 26 % EBITDA million 9.7 10.2 5 % EBIT million 6.2 6.9

More information

FINANCIAL INFORMATION FOR THE FIRST QUARTER 2015 (Condensed and Unaudited)

FINANCIAL INFORMATION FOR THE FIRST QUARTER 2015 (Condensed and Unaudited) FINANCIAL INFORMATION FOR THE FIRST QUARTER 2015 (Condensed and Unaudited) Page Financial Statements (IFRS, Unaudited) Consolidated Income Statements Consolidated Statements of Financial Position Consolidated

More information

KOREAN AIR LINES CO., LTD. AND SUBSIDIARIES. Consolidated Financial Statements

KOREAN AIR LINES CO., LTD. AND SUBSIDIARIES. Consolidated Financial Statements Consolidated Financial Statements December 31, 2015 (With Independent Auditors Report Thereon) Contents Page Independent Auditors Report 1 Consolidated Statements of Financial Position 3 Consolidated Statements

More information

Quarterly Financial Report of Fresenius Group

Quarterly Financial Report of Fresenius Group Quarterly Financial Report of Fresenius Group applying United States Generally Accepted Accounting Principles (U.S. GAAP) 1 st Quarter 2015 2 TABLE OF CONTENTS 3 Fresenius Group figures at a glance 5 Fresenius

More information

CONSOLIDATED STATEMENT OF INCOME

CONSOLIDATED STATEMENT OF INCOME CONSOLIDATED STATEMENT OF INCOME Notes Sales 1) 5,429,574 5,169,545 Cost of Goods Sold 2) 3,041,622 2,824,771 Gross Profit 2,387,952 2,344,774 Selling Expenses 3) 1,437,010 1,381,132 General and Administrative

More information

FY 2014-2015 press release

FY 2014-2015 press release FY 2014-2015 press release (Results for the year ended 31 March 2015) Press release May 29, 2015 Huizingen, Belgium Under embargo until May 29, 2015 1,8 year-over-year turnover growth resulting from 9,6

More information

Consolidated financial statements

Consolidated financial statements Summary of significant accounting policies Basis of preparation DSM s consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted

More information

STATEMENT ON FINANCIAL POSITION

STATEMENT ON FINANCIAL POSITION STATEMENT ON FINANCIAL POSITION DESCRIPTION NOTE DAY 30.06.2013 31.12.2012 Fixed assets 218 532 221 493 214 682 Intangibles 3 583 3 057 3 033 Tangible fixed assets 2 69 812 69 272 63 027 Investment properties

More information

Financial Statement Analysis Paper

Financial Statement Analysis Paper Financial Statement Analysis Paper Example 1: Dell Computer Dell Inc. Current Year Prior Year Income Statement 3 Years Ago $ Percent $ Percent $ Percent Revenue 61,494 100.0% 52,902 100.0% 61,101 100.0%

More information

TO OUR SHAREHOLDERS PROFITABLE GROWTH COURSE INTERNATIONALIZATION FURTHER EXTENDED US MARKET IN FOCUS

TO OUR SHAREHOLDERS PROFITABLE GROWTH COURSE INTERNATIONALIZATION FURTHER EXTENDED US MARKET IN FOCUS QUARTERLY STATEMENT AS OF MARCH 31, 2015 TO OUR SHAREHOLDERS Patrik Heider, Spokesman of the Executive Board and CFOO The Nemetschek Group has made a dynamic start in the 2015 financial year and continues

More information

Cash Flow Statements

Cash Flow Statements STATUTORY BOARD FINANCIAL SB-FRS 7 REPORTING STANDARD Cash Flow Statements SB-FRS 7 Cash Flow Statements applies to Statutory Boards for annual periods beginning on or after 1 January 2009. This Standard

More information

Interim Report 201. Celesio AG. report as of 30 September 2015

Interim Report 201. Celesio AG. report as of 30 September 2015 Interim Report 201 Celesio AG H1 Half-year financial report as of 30 September 2015 The Celesio Group Celesio is a leading international wholesale and retail company and provider of logistics and services

More information

Consolidated Financial Results for the First Two Quarters of the Fiscal Year Ending March 31, 2016 (Japan GAAP)

Consolidated Financial Results for the First Two Quarters of the Fiscal Year Ending March 31, 2016 (Japan GAAP) Consolidated Financial Results for the First Two Quarters of the Fiscal Year Ending March 31, 2016 (Japan GAAP) Name of Listed Company: Yokogawa Electric Corporation (the Company herein) Stock Exchanges

More information

Significant reduction in net loss

Significant reduction in net loss press release 12 May 2015 Royal Imtech publishes first quarter 2015 results Significant reduction in net loss Order intake in Q1 at a satisfactorily level of 912 million Revenue 3% down excluding Germany

More information

NEPAL ACCOUNTING STANDARDS ON CASH FLOW STATEMENTS

NEPAL ACCOUNTING STANDARDS ON CASH FLOW STATEMENTS NAS 03 NEPAL ACCOUNTING STANDARDS ON CASH FLOW STATEMENTS CONTENTS Paragraphs OBJECTIVE SCOPE 1-3 BENEFITS OF CASH FLOWS INFORMATION 4-5 DEFINITIONS 6-9 Cash and cash equivalents 7-9 PRESENTATION OF A

More information

Indian Accounting Standard (Ind AS) 7 Statement of Cash Flows

Indian Accounting Standard (Ind AS) 7 Statement of Cash Flows Contents Indian Accounting Standard (Ind AS) 7 Statement of Cash Flows Paragraphs OBJECTIVE SCOPE 1 3 BENEFITS OF CASH FLOW INFORMATION 4 5 DEFINITIONS 6 9 Cash and cash equivalents 7 9 PRESENTATION OF

More information

Condensed consolidated income statement

Condensed consolidated income statement RESTATED AND PREVIOUSLY COMMUNICATED (OLD) QUARTERLY INFORMATION FOR Fortum signed the agreement to sell its Swedish distribution business on 13 March 2015, which concludes Fortum s divestment of its electricity

More information

SanDisk Corporation Preliminary Condensed Consolidated Statements of Operations (in thousands, except per share amounts, unaudited)

SanDisk Corporation Preliminary Condensed Consolidated Statements of Operations (in thousands, except per share amounts, unaudited) Preliminary Condensed Consolidated Statements of Operations (in thousands, except per share amounts, unaudited) Revenue $ 1,634,011 $ 1,476,263 $ 3,145,956 $ 2,816,992 Cost of revenue 854,640 789,614 1,595,679

More information

ACER INCORPORATED AND SUBSIDIARIES. Consolidated Balance Sheets

ACER INCORPORATED AND SUBSIDIARIES. Consolidated Balance Sheets Consolidated Balance Sheets June 30, 2015, December 31, 2014, and (June 30, 2015 and 2014 are reviewed, not audited) Assets 2015.6.30 2014.12.31 2014.6.30 Current assets: Cash and cash equivalents $ 36,400,657

More information

Q1 2015 INTERIM REPORT JANUARY MARCH

Q1 2015 INTERIM REPORT JANUARY MARCH Q1 2015 INTERIM REPORT JANUARY MARCH 2 Contents GENERAL Business Developments Overview 3 Beiersdorf s Shares 4 INTERIM MANAGEMENT REPORT GROUP Results of Operations Group 5 Results of Operations Business

More information

GE Capital. Second quarter 2012 supplement

GE Capital. Second quarter 2012 supplement GE Capital Second quarter supplement Results are unaudited. This document contains forward-looking statements that is, statements related to future, not past, events. In this context, forward-looking statements

More information

Sri Lanka Accounting Standard-LKAS 7. Statement of Cash Flows

Sri Lanka Accounting Standard-LKAS 7. Statement of Cash Flows Sri Lanka Accounting Standard-LKAS 7 Statement of Cash Flows CONTENTS SRI LANKA ACCOUNTING STANDARD-LKAS 7 STATEMENT OF CASH FLOWS paragraphs OBJECTIVE SCOPE 1 3 BENEFITS OF CASH FLOW INFORMATION 4 5 DEFINITIONS

More information

Statement of Cash Flows

Statement of Cash Flows STATUTORY BOARD FINANCIAL REPORTING STANDARD SB-FRS 7 Statement of Cash Flows This version of SB-FRS 7 does not include amendments that are effective for annual periods beginning after 1 January 2014.

More information

617-444-3913 617-274-7130 AKAMAI REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS

617-444-3913 617-274-7130 AKAMAI REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS FOR IMMEDIATE RELEASE Contacts: Jeff Young Tom Barth Media Relations Investor Relations Akamai Technologies Akamai Technologies 617-444-3913 617-274-7130 jyoung@akamai.com tbarth@akamai.com AKAMAI REPORTS

More information

Quarterly Financial Report March 31, 2009. MBB Industries AG. Berlin

Quarterly Financial Report March 31, 2009. MBB Industries AG. Berlin Quarterly Financial Report March 31, 2009 MBB Industries AG. Berlin Quarterly Financial Report March 31, 2009 MBB Industries AG MBB Industries in Numbers 03 MBB Industries in Numbers Three Month (Jan.

More information

Operating and Financial Review

Operating and Financial Review Financial Section Operating and Financial Review Operating Results The Company s consolidated financial statements have been prepared in conformity with IFRS since the year ended March 31, 2015. The figures

More information

HOSOKAWA MICRON CORPORATION AND CONSOLIDATED SUBSIDIARIES

HOSOKAWA MICRON CORPORATION AND CONSOLIDATED SUBSIDIARIES AND CONSOLIDATED SUBSIDIARIES Consolidated Financial Statements For the Years Ended December 2016 Consolidated Balance Sheets Current assets: Millions of yen Thousands of U.S. dollars (Note 1) Assets 2016

More information

IBM REPORTS 2014 FOURTH-QUARTER AND FULL-YEAR RESULTS

IBM REPORTS 2014 FOURTH-QUARTER AND FULL-YEAR RESULTS IBM REPORTS 2014 FOURTH-QUARTER AND FULL-YEAR RESULTS Fourth-Quarter 2014: o Diluted EPS from continuing operations: - GAAP: $5.54, down 4 percent; - Operating (non-gaap): $5.81, down 6 percent; o Pre-tax

More information

DATA GROUP LTD. ANNOUNCES FIRST QUARTER RESULTS FOR 2014

DATA GROUP LTD. ANNOUNCES FIRST QUARTER RESULTS FOR 2014 For Immediate Release DATA GROUP LTD. ANNOUNCES FIRST QUARTER RESULTS FOR 2014 HIGHLIGHTS Q1 2014 First quarter 2014 ( Q1 ) Revenues of 77.9 million, Q1 Gross Profit of 18.8 million and Q1 Net Income of

More information

Summary of Consolidated Financial Results for the Six Months Ended September 30, 2016 (Based on Japanese GAAP)

Summary of Consolidated Financial Results for the Six Months Ended September 30, 2016 (Based on Japanese GAAP) Translation Notice: This document is an excerpt translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the

More information

As of December 31, 2014. As of December 31, 2015. Assets Current assets:

As of December 31, 2014. As of December 31, 2015. Assets Current assets: Assets Current assets: Alphabet Inc. CONSOLIDATED BALANCE SHEETS (In millions, except share and par value amounts which are reflected in thousands, and par value per share amounts) As of December 31, 2014

More information

5. Statement of Cash Flows Analysis

5. Statement of Cash Flows Analysis 5. Statement of Cash Flows Analysis Table 9. Consolidated Statements of Cash Flows THE COCA-COLA COMPANY CONSOLIDATED STATEMENTS OF CASH FLOWS Year Ended December 31, OPERATING ACTIVITIES CONSOLIDATED

More information

Half-yearly Financial Report. January 1 June 30, 2014. engineering for a better world

Half-yearly Financial Report. January 1 June 30, 2014. engineering for a better world Half-yearly Financial Report January 1 June 30, engineering for a better world GEA Group: Key IFRS figures GEA Group: Key IFRS figures (EUR million) Q2 Q2 1 Q1-Q2 Q1-Q2 1 Results of operations Order intake

More information

KYODO PRINTING CO., LTD. and Consolidated Subsidiaries

KYODO PRINTING CO., LTD. and Consolidated Subsidiaries KYODO PRINTING CO., LTD. and Consolidated Subsidiaries Interim Consolidated Financial Statements (Unaudited) for the, Interim Consolidated Balance Sheets, as compared with March 31, (Unaudited) ASSETS,

More information

November 4, 2015 Consolidated Financial Results for the Second Quarter of Fiscal Year 2015 (From April 1, 2015 to September 30, 2015) [Japan GAAP]

November 4, 2015 Consolidated Financial Results for the Second Quarter of Fiscal Year 2015 (From April 1, 2015 to September 30, 2015) [Japan GAAP] November 4, 2015 Consolidated Financial Results for the Second Quarter of Fiscal Year 2015 (From April 1, 2015 to September 30, 2015) [Japan GAAP] Company Name: Idemitsu Kosan Co., Ltd. (URL http://www.idemitsu.com)

More information

DELL INC. Condensed Consolidated Statement of Income and Related Financial Highlights (in millions, except per share data and percentages) (unaudited)

DELL INC. Condensed Consolidated Statement of Income and Related Financial Highlights (in millions, except per share data and percentages) (unaudited) Condensed Consolidated Statement of Income and Related Financial Highlights (in millions, except per share data and percentages) Three Months Ended % Growth Rates August 2, May 3, August 3, 2013 2013 2012

More information

Consolidated sales of 6,347 million euros, up 10% on a like-for-like basis (7% as reported)

Consolidated sales of 6,347 million euros, up 10% on a like-for-like basis (7% as reported) 14.18 Order intake surged 25% to 9.1 billion euros Sales came in at 6.3 billion euros, up 10% like for like (7% as reported) Operating margin (1) up 15% to 442 million euros, or 7.0% of sales Net income

More information

Summary of Consolidated Financial Results for the First Half Ended September 30, 2013 (IFRS) November 6, 2013

Summary of Consolidated Financial Results for the First Half Ended September 30, 2013 (IFRS) November 6, 2013 Summary of Consolidated Financial Results for the First Half Ended September 30, 2013 (IFRS) November 6, 2013 Sojitz Corporation ( URL http://www.sojitz.com ) Listed stock exchange: The first sections

More information

DATA GROUP INC. ANNOUNCES FULL YEAR AND FOURTH QUARTER RESULTS FOR 2012

DATA GROUP INC. ANNOUNCES FULL YEAR AND FOURTH QUARTER RESULTS FOR 2012 For Immediate Release HIGHLIGHTS DATA GROUP INC. ANNOUNCES FULL YEAR AND FOURTH QUARTER RESULTS FOR 2012 Full Year 2012 Revenues of 336.3 million, Gross Profit of 87.2 million, and Net Loss of 37.1 million

More information

Tower International Reports Solid Third Quarter And Raises Full Year Outlook

Tower International Reports Solid Third Quarter And Raises Full Year Outlook FOR IMMEDIATE RELEASE Tower International Reports Solid Third Quarter And Raises Full Year Outlook LIVONIA, Mich., November 3, 2011 Tower International, Inc. [NYSE: TOWR], a leading integrated global manufacturer

More information

Group Quarterly Statement January September 2016

Group Quarterly Statement January September 2016 Sharing values Growing Together Group Quarterly Statement January September 2016 Group sales increase 11 % to 2,192 million 16 % sales growth at local currency EBITDAN up 7 % to 480 million EBITDAN margin

More information

ACC 255 FINAL EXAM REVIEW PACKET (NEW MATERIAL)

ACC 255 FINAL EXAM REVIEW PACKET (NEW MATERIAL) Page 1 ACC 255 FINAL EXAM REVIEW PACKET (NEW MATERIAL) Complete these sample exam problems/objective questions and check your answers with the solutions at the end of the review file and identify where

More information

CORNING INCORPORATED AND SUBSIDIARY COMPANIES CONSOLIDATED STATEMENTS OF INCOME (Unaudited; in millions, except per share amounts)

CORNING INCORPORATED AND SUBSIDIARY COMPANIES CONSOLIDATED STATEMENTS OF INCOME (Unaudited; in millions, except per share amounts) CONSOLIDATED STATEMENTS OF INCOME (Unaudited; in millions, except per share amounts) Three months ended Nine months ended 2013 2012 2013 2012 sales $ 2,067 $ 2,038 $ 5,863 $ 5,866 Cost of sales 1,166 1,149

More information

UNDERSTANDING CANADIAN PUBLIC SECTOR FINANCIAL STATEMENTS

UNDERSTANDING CANADIAN PUBLIC SECTOR FINANCIAL STATEMENTS June 2014 UNDERSTANDING CANADIAN PUBLIC SECTOR FINANCIAL STATEMENTS www.bcauditor.com TABLE OF CONTENTS Who Will Find this Guide Helpful 3 What a Set of Public Sector Financial Statements Includes 5 The

More information

Contact 6-Month Report 2005

Contact 6-Month Report 2005 Contact 6-Month Report 2005 Security Networks AG Kronprinzenstrasse 30 45128 ssen Germany Phone: +49 (0) 201 54 54-0 Fax: +49 (0) 201 54 54-456 Internet: www..com -mail: investor.relations@.com Key figures

More information

Scania Interim Report, January March 2015

Scania Interim Report, January March 2015 23 April 2015 Scania Interim Report, January March 2015 Summary of the first three months of 2015 Operating income decreased by 1 percent to SEK 2,245 m. (2,257) Net sales rose by 6 percent to SEK 22,321

More information

H1 2015 INTERIM REPORT JANUARY JUNE

H1 2015 INTERIM REPORT JANUARY JUNE H1 2015 INTERIM REPORT JANUARY JUNE 2 Contents GENERAL Business Developments Overview 3 Beiersdorf s Shares 4 INTERIM MANAGEMENT REPORT GROUP Results of Operations Group 5 Results of Operations Business

More information

Logwin AG. Interim Financial Report as of 31 March 2015

Logwin AG. Interim Financial Report as of 31 March 2015 Logwin AG Interim Financial Report as of 31 March 2015 Key Figures 1 January 31 March 2015 Earnings position In thousand EUR 2015 2014 Revenues Group 274,433 278,533 Change on 2014-1.5% Solutions 101,821

More information

Conference call on the first six months 2015»

Conference call on the first six months 2015» Conference call on the first six months 2015» EnBW Energie Baden-Württemberg AG Karlsruhe, 30 July 2015 Thomas Kusterer, Chief Financial Officer Ingo Peter Voigt, Senior Vice President, Head of Finance,

More information

Non-GAAP Financial Measures. Second Quarter and First Half of Fiscal 2014. siemens.com. Energy efficiency. Intelligent infrastructure solutions

Non-GAAP Financial Measures. Second Quarter and First Half of Fiscal 2014. siemens.com. Energy efficiency. Intelligent infrastructure solutions Energy efficiency Next-generation healthcare Industrial productivity Intelligent infrastructure solutions Non-GAAP Financial Measures Second Quarter and First Half of Fiscal 2014 siemens.com second QUARTER

More information

WESTERN DIGITAL CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS. (in millions; unaudited) ASSETS

WESTERN DIGITAL CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS. (in millions; unaudited) ASSETS CONDENSED CONSOLIDATED BALANCE SHEETS (in millions; unaudited) ASSETS Apr. 1, July 3, 2016 2015 Current assets: Cash and cash equivalents $ 5,887 $ 5,024 Short-term investments 146 262 Accounts receivable,

More information

1 CONSOLIDATED FINANCIAL STATEMENTS (1) Consolidated Balance Sheets

1 CONSOLIDATED FINANCIAL STATEMENTS (1) Consolidated Balance Sheets 1 CONSOLIDATED FINANCIAL STATEMENTS (1) Consolidated Balance Sheets As of March 31,2014 As of March 31,2015 Assets Cash and due from banks 478,425 339,266 Call loans and bills bought 23,088 58,740 Monetary

More information

FINANCIAL RESULTS FOR THE THREE MONTHS ENDED JUNE 2015

FINANCIAL RESULTS FOR THE THREE MONTHS ENDED JUNE 2015 FINANCIAL RESULTS FOR THE THREE MONTHS ENDED JUNE 2015 Mitsubishi Corporation 2-3-1 Marunouchi, Chiyoda-ku, Tokyo, JAPAN 100-8086 http://www.mitsubishicorp.com/ FINANCIAL HIGHLIGHTS FOR THE THREE MONTHS

More information

FINANCIAL INFORMATION CONSOLIDATED FINANCIAL STATEMENTS. Risk management

FINANCIAL INFORMATION CONSOLIDATED FINANCIAL STATEMENTS. Risk management 167 Risk management Group risk management Group Risk Management supports the Board of Directors, the Executive Committee and the management teams of the Group companies in their strategic decisions. Group

More information